Organon to be Acquired by Sun Pharma for $14.00/Share in All-Cash Deal, Valuing Company at $11.75B

summarizeSummary

Organon & Co. has entered into a definitive merger agreement to be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in an all-cash transaction, representing an enterprise value of $11.75 billion.

check_boxKey Events

• Definitive Merger Agreement Signed

  Organon & Co. has entered into a definitive Agreement and Plan of Merger to be acquired by Sun Pharmaceutical Holdings USA, Inc.

• All-Cash Acquisition at $14.00 Per Share

  Each outstanding share of Organon common stock will be converted into the right to receive $14.00 in cash, representing a premium over the current trading price and the unaffected share price.

• $11.75 Billion Enterprise Valuation

  The transaction values Organon at an enterprise value of $11.75 billion, significantly exceeding its current market capitalization.

• Leadership Roles Confirmed

  Joseph Morrissey has been permanently appointed Chief Executive Officer and Carrie S. Cox as Executive Chair, confirming their interim roles.

auto_awesomeAnalysis

This 8-K officially announces the definitive merger agreement for Organon & Co. to be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash. This all-cash transaction, with an enterprise value of $11.75 billion, represents a significant premium over the company's unaffected share price and a notable premium over the current trading price of $13.0495. The acquisition will result in Organon becoming a wholly-owned subsidiary of Sun Pharma, providing a clear exit for current shareholders. The deal is subject to regulatory approvals and Organon stockholder approval, with an expected close in early 2027. This is a transformational event for Organon, fundamentally altering its future as an independent public entity. The stock is currently trading near its 52-week high, and the acquisition price offers a further upside for shareholders.